- Trial Phase
- Phase 1/2
- Time to Market
- At least 3-5 years. COM701 is in Phase 1/2 (MAIA trial); even with positive interim data in Q1 2027, a registrational Phase 3 trial and FDA review would follow, putting potential approval in the 2029-2031 timeframe.
- Why 7/10
- The next hard, dated catalyst is the MAIA-ovarian interim PFS analysis expected by Q1 2027 (~4-6 months from now). COM701 is Compugen's wholly-owned lead asset and a major value driver, but the company also has partnered programs (rilvegostomig with AstraZeneca, GS-0321 with Gilead) that provide diversification, so the score is 7 rather than 8-9.
The next hard catalyst for COM701 is the MAIA-ovarian interim PFS analysis expected by Q1 2027 — roughly 4-6 months out. Positive data could drive a significant re-rating given the strong analyst consensus (10 Buy/Strong Buy vs 1 Hold) and ~41% implied upside to the $4.60 mean price target. Negative data would be a major setback for Compugen's wholly-owned pipeline. Monitor for any pre-announcements or delays.
Price Chart
Executive Summary
COM701 is Compugen's wholly-owned anti-PVRIG checkpoint inhibitor immunotherapy, currently being evaluated in the MAIA Phase 1/2 trial for ovarian cancer. The next major catalyst is the interim progression-free survival (PFS) analysis expected by Q1 2027. Compugen has a strong cash position ($125.3M, runway into 2029) and a robust analyst consensus (10 Buy/Strong Buy, mean PT $4.60 vs ~$2.84 current price). However, elevated short volume and the binary nature of the upcoming readout create significant risk. The company also has partnered programs (AstraZeneca's rilvegostomig, Gilead's GS-0321) that provide pipeline diversification.
How It Works
COM701 is a monoclonal antibody (a lab-made immune protein) designed to block a protein called PVRIG on immune T cells. Tumors often use PVRIG's partner protein (PVRL2) to send a 'don't attack' signal that disarms the immune system. By blocking PVRIG, COM701 removes that brake, allowing T cells to recognize and kill cancer cells. It is a type of immunotherapy called a checkpoint inhibitor, similar in concept to PD-1/PD-L1 blockers but targeting a different pathway.
Trial Status
COM701 is being studied in the MAIA trial (NCT identifier not available in local data), a Phase 1/2 study evaluating COM701 in combination with nivolumab (Opdivo) in patients with advanced solid tumors, with a focus on platinum-resistant ovarian cancer. The interim progression-free survival (PFS) analysis is expected by Q1 2027, per Compugen's Q2 2026 earnings update.
The Two-Sided Case
Upcoming Catalysts
- MAIA-ovarian interim PFS analysis for COM701 — expected by Q1 2027
- Potential partnership or licensing deal for COM701 (Compugen has a history of partnerships with AZ, Gilead, BMS)
- Annual General Meeting on September 10, 2026 (routine governance, low impact)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
COMPUGEN LTD 6-K CGEN ·Originating report